↑ 薬物リストへ　← 戻る

Lamotrigine dispers    (DrugBank: Lamotrigine)

5 diseases
告示番号疾患名（ページ内リンク）臨床試験数
13多発性硬化症／視神経脊髄炎0
34神経線維腫症4
38スティーヴンス・ジョンソン症候群0
114非ジストロフィー性ミオトニー症候群0
144レノックス・ガストー症候群0

13. 多発性硬化症／視神経脊髄炎　［臨床試験数：3,050，薬物数：2,147（DrugBank：348），標的遺伝子数：244，標的パスウェイ数：228］
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 3,050 trial found

34. 神経線維腫症　［臨床試験数：120，薬物数：182（DrugBank：72），標的遺伝子数：84，標的パスウェイ数：194］
Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 120 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2013-003405-26-DK
(EUCTR)		22/02/201824/04/2017Treating learning disabilities in Neurofibromatosis 1 using lamotrigineThe effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) - Treating learning disabilities in Neurofibromatosis 1 using lamotrigine Neurofibromatosis type 1
MedDRA version: 20.0;Level: LLT;Classification code 10029270;Term: Neurofibromatosis, type 1 (von Recklinghausen's disease);System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]		Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
INN or Proposed INN: lamotrigine
Other descriptive name: LAMOTRIGINE		Erasmus MCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		60Phase 2Spain;Belgium;Denmark;Netherlands
2EUCTR2013-003405-26-ES
(EUCTR)		16/10/201731/07/2017Treating learning disabilities in Neurofibromatosis 1 using lamotrigineThe effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) Neurofibromatosis type 1
MedDRA version: 20.0;Level: LLT;Classification code 10029270;Term: Neurofibromatosis, type 1 (von Recklinghausen's disease);System Organ Class: 100000012614;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]		Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE		Erasmus MCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		60Phase 2Belgium;Spain;Netherlands
3EUCTR2013-003405-26-BE
(EUCTR)		30/04/201530/03/2015Treating learning disabilities in Neurofibromatosis 1 using lamotrigineThe effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) Neurofibromatosis type 1
MedDRA version: 17.1;Level: LLT;Classification code 10029270;Term: Neurofibromatosis, type 1 (von Recklinghausen's disease);System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]		Trade Name: Lamotrigine dispersErasmus MCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		60Phase 2Belgium;Netherlands
4EUCTR2013-003405-26-NL
(EUCTR)		03/09/201420/09/2013Treating learning disabilities in Neurofibromatosis 1 using lamotrigineThe effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) Neurofibromatosis type 1
MedDRA version: 17.0;Level: LLT;Classification code 10029270;Term: Neurofibromatosis, type 1 (von Recklinghausen's disease);System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]		Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
INN or Proposed INN: lamotrigine
Other descriptive name: LAMOTRIGINE		Erasmus MCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		60Phase 2Netherlands

38. スティーヴンス・ジョンソン症候群　［臨床試験数：11，薬物数：19（DrugBank：8），標的遺伝子数：14，標的パスウェイ数：98］
Searched query = "Stevens-Johnson syndrome", "SJS", "Mucocutaneous ocular syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 11 trial found

114. 非ジストロフィー性ミオトニー症候群　［臨床試験数：10，薬物数：14（DrugBank：5），標的遺伝子数：18，標的パスウェイ数：10］
Searched query = "Non-dystrophic myotonia syndrome", "Non-dystrophic Myotonia", "Myotonia congenita", "Thomsen disease", "Becker disease", "Paramyotonia congenita", "Sodium channel myotonia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 10 trial found

144. レノックス・ガストー症候群　［臨床試験数：80，薬物数：63（DrugBank：11），標的遺伝子数：49，標的パスウェイ数：59］
Searched query = "Lennox-Gastaut syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 80 trial found